Editorial Board member, Ulka Vaishampayan, talks to us at the ASCO 2019 annual meeting about recent advances in prostate and kidney cancer. Discussing the rationale for apalutamide addition in metastatic castration-sensitive prostate cancer alongside the findings from the TITAN study (NCT02489318) she highlights the impact these results will have on clinical practice. Further data presented from the CARMENA trial (NCT00930033) at the meeting are also discussed alongside how the overall study has affected the management of metastatic renal cell carcinoma.
1. What is the rationale for the addition of apalutamide to androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer? (0:04)
2. What were the major efficacy and safety findings of the TITAN study? (0:36)
3. What impact will these findings have on clinical practice? (1:36)
4. How have the findings of the CARMENA trial affected the role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma (RCC)? (2:41)
5.Could you tell us about the update on the CARMENA trial in the intermediate IMDC-risk population? (4:18)
Speaker disclosure: Ulka Vaishampaya has received honoraria and acted as a consultant for Pfizer, Bayer, Exelixis, BMS and Eisai. She has also received research support from BMS, Amgen, Exelixis and Astellas.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Genitourinary Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of […]
Enrique Grande, ESMO 2022: Post-hoc analysis investigating PD-L1 expression on immune cells, and improved OS with atezolizumab in patients with urothelial cancer
PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!